Evidence map›Paper›PMID 29309770›Full record

Trial reportNeuropharmacology2018

A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

E Dakwar, E V Nunes, C L Hart, M C Hu, R W Foltin, F R Levin

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 6 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 6 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

E DakwarNew York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, USA. Electronic address: dakware@nyspi.columbia.edu.
E V NunesNew York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, USA.
C L HartNew York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, USA; Department of Psychology, Columbia University, USA.
M C HuDepartment of Psychology, Columbia University, USA.
R W FoltinNew York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, USA.
F R LevinNew York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, USA.
Columbia University · US

Funding

Substance Abuse Treatment Development and Clinical Research MentoringK24DA029647 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LEVIN, FRANCES RUDNICK · 2010 to 2019
$1.8M
Brief Potent Glutamatergic Modulation: Applications for Cocaine DependenceK23DA031771 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI DAKWAR, ELIAS · 2011 to 2015
$931k
The Effect of Glutamatergic Modulation on Cocaine Self-AdministrationR21DA035472 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI DAKWAR, ELIAS · 2013 to 2014
$426k
NIDA NIH HHS K23 DA031771NIDA NIH HHS K24 DA029647NIDA NIH HHS L30 DA034204NIDA NIH HHS R21 DA035472
6 · The paper itself

Abstract

Efforts to translate sub-anesthetic ketamine infusions into widespread clinical use have centered around developing medications with comparable neurobiological activity, but with attenuated psychoactive effects so as to minimize the risk of behavioral toxicity and abuse liability. Converging lines of research, however, suggest that some of the psychoactive effects of sub-anesthetic ketamine may have therapeutic potential. Here, we assess whether a subset of these effects - the so-called mystical-type experience - mediates the effect of ketamine on craving and cocaine use in cocaine dependent research volunteers. We found that ketamine leads to significantly greater acute mystical-type effects (by Hood Mysticism Scale: HMS), dissociation (by Clinician Administered Dissociative States Scale: CADSS), and near-death experience phenomena (by the Near-Death Experience Scale: NDES), relative to the active control midazolam. HMS score, but not the CADSS or NDES score, was found to mediate the effect of ketamine on global improvement (decreased cocaine use and craving) over the post-infusion period. This is the first controlled study to show that mystical-type phenomena, long considered to have therapeutic potential, may work to impact decision-making and behavior in a sustained manner. These data suggest that an important direction for medication development is the identification of ketamine-like pharmacotherapy that is selectively psychoactive (as opposed to free of experiential effects entirely), so that mystical-type perspectival shifts are more reliably produced and factors lending to abuse or behavioral impairment are minimized. Future research can further clarify the relationship between medication-occasioned mystical-type effects and clinical benefit for different disorders. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.

Indexed as

Cocaine-Related DisordersDissociative DisordersFemaleHallucinogensHospitalizationHumansKetamineMaleMidazolamMiddle AgedMysticismTreatment OutcomeHallucinogensKetamineMidazolamAddictionCocaineHallucinogenKetamineMystical experiencePsychedelicPsychoactive effects

Identifiers

PMID29309770
PMCPMC6033686
OpenAlexW2782003333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.